These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 26439700)

  • 81. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
    Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
    Ajani JA; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Awad L; Van Cutsem E;
    J Clin Oncol; 2007 Aug; 25(22):3210-6. PubMed ID: 17664468
    [TBL] [Abstract][Full Text] [Related]  

  • 83. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
    Kim GM; Jeung HC; Rha SY; Kim HS; Jung I; Nam BH; Lee KH; Chung HC
    Eur J Cancer; 2012 Mar; 48(4):518-26. PubMed ID: 22243774
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [A case of advanced adenocarcinoma of esophagogastric junction with severe esophageal invasion effectively treated by chemoradiotherapy using paclitaxel and cisplatin, and S-1 after chemoradiotherapy].
    Fujiwara H; Koeda K; Konosu M; Hosoi N; Tamasawa Y; Sase M; Tsukahara T; Ushio A; Taguchi M; Wakabayashi G
    Gan To Kagaku Ryoho; 2011 Oct; 38(10):1683-6. PubMed ID: 21996967
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.
    Seol YM; Song MK; Choi YJ; Kim GH; Shin HJ; Song GA; Chung JS; Cho GJ
    Jpn J Clin Oncol; 2009 Jan; 39(1):43-8. PubMed ID: 18997184
    [TBL] [Abstract][Full Text] [Related]  

  • 86. S-1 plus oxaliplatin vs. S-1 as first-line treatment in patients with previously untreated advanced gastric cancer: a randomized phase II study.
    Lu Y; Liu Z; Zhang J
    J Chemother; 2014 Jun; 26(3):159-64. PubMed ID: 24621155
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
    Shah MA; Cho JY; Tan IB; Tebbutt NC; Yen CJ; Kang A; Shames DS; Bu L; Kang YK
    Oncologist; 2016 Sep; 21(9):1085-90. PubMed ID: 27401892
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial).
    Higuchi K; Tanabe S; Shimada K; Hosaka H; Sasaki E; Nakayama N; Takeda Y; Moriwaki T; Amagai K; Sekikawa T; Sakuyama T; Kanda T; Sasaki T; Azuma M; Takahashi F; Takeuchi M; Koizumi W;
    Eur J Cancer; 2014 May; 50(8):1437-45. PubMed ID: 24560487
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma].
    Jiang Y; Qiu XH; Yang YX; Zhang SQ; Chen ZM
    Ai Zheng; 2006 Aug; 25(8):1029-34. PubMed ID: 16965688
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer].
    Zhou Y; Huang J; Yang L; Chi Y; Qu T; Lü X; Wang JW
    Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):860-4. PubMed ID: 23291138
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [A comparative study of S-1 plus cisplatin and S-1 plus weekly cisplatin for unresectable gastric cancer].
    Kemmochi T; Egawa T; Sato A; Umakoshi T; Ito Y; Nagashima A; Makino H; Yamamuro W
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):2307-9. PubMed ID: 23268059
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Biweekly Docetaxel and S-1 combination chemotherapy as first-line treatment for elderly patients with advanced gastric cancer.
    Kunisaki C; Takahashi M; Ono HA; Hasegawa S; Tsuchida K; Oshima T; Ota M; Fukushima T; Tokuhisa M; Izumisawa Y; Takagawa R; Kimura J; Kosaka T; Makino H; Akiyama H; Endo I
    Anticancer Res; 2013 Feb; 33(2):697-704. PubMed ID: 23393370
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
    Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
    Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Moderate neutropenia with S-1 plus low-dose cisplatin may predict a more favourable prognosis in advanced gastric cancer.
    Nakata B; Tsuji A; Mitachi Y; Yamamitsu S; Hirata K; Takeuchi T; Shirasaka T; Hirakawa K
    Clin Oncol (R Coll Radiol); 2006 Nov; 18(9):678-83. PubMed ID: 17100153
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study.
    Jiang Z; Zhou A; Sun Y; Zhang W
    BMC Cancer; 2022 Mar; 22(1):253. PubMed ID: 35264150
    [TBL] [Abstract][Full Text] [Related]  

  • 96. S-1 in Patients with Advanced Esophagogastric Adenocarcinoma: Results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study.
    Venerito M
    Drugs R D; 2019 Jun; 19(2):141-148. PubMed ID: 30825156
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway.
    He MM; Zhang DS; Wang F; Wang ZX; Yuan SQ; Wang ZQ; Luo HY; Ren C; Qiu MZ; Jin Y; Wang DS; Chen DL; Zeng ZL; Li YH; He YY; Hao YT; Guo P; Wang FH; Zeng YX; Xu RH
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):69-79. PubMed ID: 27913881
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.
    Ter Veer E; Haj Mohammad N; van Valkenhoef G; Ngai LL; Mali RMA; Anderegg MC; van Oijen MGH; van Laarhoven HWM
    J Natl Cancer Inst; 2016 Oct; 108(10):. PubMed ID: 27576566
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer.
    Jiang DM; Sim HW; Espin-Garcia O; Chan BA; Natori A; Lim CH; Moignard S; Chen EX; Liu G; Darling G; Swallow CJ; Brar S; Brierley J; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Knox JJ; Jang RW; Elimova E
    Oncology; 2021; 99(1):49-56. PubMed ID: 33053548
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114).
    Heinrich K; Heinemann V; Stintzing S; Müller L; Ettrich TJ; Büchner-Steudel P; Geißler M; Trojan J; Moosmann N; Folprecht G; Schmidt J; Kanzler S; Kullmann F; Moulin JC; Werner J; Angele MK; Probst V; Held S; Schulz C; Boukovala M
    Oncol Res Treat; 2024; 47(6):251-261. PubMed ID: 38565089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.